Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies

PURPOSE: This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone deacetylase abexinostat in combination with pazopanib to enhance response and reverse resistance. PATIENTS AND METHODS: Pazopanib was administered...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Aggarwal, Rahul, Thomas, Scott, Pawlowska, Nela, Bartelink, Imke, Grabowsky, Jennifer, Jahan, Thierry, Cripps, Amy, Harb, Armand, Leng, Jim, Reinert, Anne, Mastroserio, Ilaria, Truong, Thach-Giao, Ryan, Charles J., Munster, Pamela N.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5791833/
https://ncbi.nlm.nih.gov/pubmed/28221861
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.5350
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados